Best Fisetin Supplements for Cellular Aging in 2026

Fisetin is a naturally occurring flavonoid found in strawberries, apples, and persimmons — though dietary amounts are far below the doses used in clinical research. Its longevity-relevant effects operate through two primary mechanisms: senolytic clearance and mTOR pathway modulation. **Senolytic mechanism: clearing zombie cells.** Senescent cells are normal cells that have stopped dividing (due to DNA damage, telomere shortening, or other stresses) but have not undergone apoptosis (programmed cell death). They accumulate with age — by some estimates comprising 1-3% of cells in aged tissue — and secrete a cocktail of inflammatory cytokines, proteases, and growth factors called the SASP (senescence-associated secretory phenotype). The SASP drives chronic low-grade inflammation ('inflammaging'), impairs tissue repair, promotes nearby cells to become senescent (bystander effect), and is increasingly recognized as a driver of age-related disease. Senescent cells survive by upregulating pro-survival signaling pathways — particularly BCL-2 family anti-apoptotic proteins (BCL-XL, BCL-W, BCL-2 itself) that suppress the normal apoptosis machinery. Fisetin inhibits these pro-survival signals, restoring the cell's ability to undergo apoptosis. It also inhibits the PI3K/AKT/mTOR pathway, which is another pro-survival signal overexpressed in senescent cells. The net result: senescent cells that were resisting death become susceptible to apoptosis and are cleared by the immune system. **Why burst dosing for senolytics?** This is the most important practical concept on this page. For fisetin's senolytic effect to occur, plasma concentrations must reach a threshold sufficient to inhibit BCL-2 family proteins in senescent cells — a higher bar than the antioxidant or anti-inflammatory activity that occurs at lower concentrations. In preclinical models, this requires brief high-dose exposure (typically equivalent to ~20mg/kg for 2 consecutive days in mice). In humans, clinical trials have used intermittent protocols of 500-1,500mg/day for 2 consecutive days, followed by a 4-8 week washout period before repeating. The rationale for the washout period: senescent cells take weeks to months to re-accumulate to baseline levels after clearance. Continuous daily dosing at low levels does not achieve the required plasma concentration threshold for senolysis — it produces antioxidant and anti-inflammatory benefits (worthwhile independently) but does not clear senescent cells by the same mechanism. **mTOR inhibition.** mTOR (mechanistic target of rapamycin) is a master regulator of cell growth, metabolism, and aging. Chronic mTOR activation is associated with accelerated cellular aging; mTOR inhibition (via rapamycin or natural compounds) is one of the most reproducible lifespan-extending interventions in model organisms. Fisetin inhibits mTORC1 — the specific complex most linked to aging — providing a second mechanism of action independent of its senolytic pathway. **Anti-inflammatory effects at daily doses.** At 100mg/day doses, fisetin acts as a flavonoid antioxidant and NF-κB inhibitor, reducing systemic inflammatory markers. This is a real benefit, but it is a different mechanism from senolytics — it reduces inflammation in existing cells rather than removing senescent cells. Both are useful; understanding the distinction prevents misinterpreting the mechanism.

**What dose of fisetin is needed for senolytic effects?** The animal research used doses equivalent to approximately 20mg/kg body weight for 2 consecutive days. For a 75kg (165 lb) adult, that translates to approximately 1,500mg/day for 2 days. The human clinical trials (AFFIRM-LITE and others) have used doses in the 500-1,500mg range over 2-day protocols. This is far above the 100mg/day dose found in most mainstream fisetin products — which is dosed for antioxidant, not senolytic, effects. Choose products with 250-500mg per capsule if the senolytic application is your goal. **How often should the burst protocol be repeated?** There is no established human protocol yet. Based on the preclinical biology (senescent cells re-accumulate over weeks to months) and the clinical trial designs (monthly to quarterly cycles), most longevity practitioners using fisetin senolytics suggest 2-day burst cycles every 4-8 weeks. Some protocols suggest quarterly (4x/year). There is no human data proving one schedule is optimal — this is informed judgment based on senescent cell biology, not established clinical guidance. **Should I take fisetin with food?** Yes — and ideally with a source of fat. Fisetin is a fat-soluble flavonoid; absorption is significantly improved when taken with dietary fat. The Toniiq product includes MCT oil to address this. For other products, take with a meal that includes healthy fat (olive oil, avocado, nuts). **Is fisetin better than quercetin for senolytics?** In the Kirkland lab head-to-head screening, fisetin outperformed quercetin for senolytic potency in the specific assays used. However, quercetin has been studied more extensively in clinical settings (the dasatinib+quercetin combination is the most-studied clinical senolytic protocol). Many longevity practitioners use both — quercetin's BCL-2 inhibition and fisetin's broader pro-survival pathway inhibition are complementary. The Life Extension Senolytic Activator on this page includes both.